Veeva Systems Inc Class A (VEEV) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of Veeva Systems Inc Class A stock $342, price $310, upside +10.2%, quality 73 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range $151.10 – $341.00 · fair‑value band $210.12 – $444.21 · the $310.10 price screens below the $341.69 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Veeva Systems Inc Class A in your weekly email
Every Wednesday you see whether Veeva Systems Inc Class A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America.
Show moreShow less
The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies; Veeva PromoMats, an end-to-end content and digital asset management solution; and Veeva Crossix, an analytics platform for pharmaceutical brands.
It also provides Veeva Data Cloud, such as Veeva OpenData, a customer reference data solution; Veeva Link, which provides deep data; Veeva Compass, which includes de-identified and longitudinal patient data; and Veeva CRM Pulse that provides access and multichannel engagement metrics.
In addition, the company offers Veeva Development Cloud consisting of Veeva Clinical Platform, which advances clinical trial execution; Veeva Clinical Data Management that helps sponsors and CROs design and run trials; Veeva Safety, which unifies systems and processes; Veeva RIM that provides regulatory information management capabilities, as well as Veeva Quality Cloud, which is used by the life sciences and consumer products industries; and Veeva Business Consulting services.
Further, it provides professional and support services, including implementation and deployment planning, and project management; requirements analysis, solution design, and configuration; systems environment management and deployment; services focused on advancing or transforming business and operating processes; technical consulting services on data migration and systems integrations; training; and ongoing managed services, such as outsourced systems administration.
The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.
Stock analysis
Veeva Systems Inc Class A (VEEV) currently trades at $310.10, while our model-based Fair Value estimate is $341.69, so the stock looks roughly fairly valued today (gap 9.2%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $193.76 per share, and 0 of the 24 models we run sit above the $310.10 price.
Bear case: the Asset-Based group reads lowest at $38.50, and 24 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $210.12 (bear) to $444.21 (bull), the price of $310.10 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 73/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Veeva Systems Inc Class A reported revenue of $3.2B in FY2026 versus $1.9B in FY2022, a compound +14.6%/yr. Reported net income was $909M in FY2026, compounding +20.8%/yr from FY2022.
Key figures
Market cap $51.8B Large · P/E ratio 50.5 · P/S ratio 15.0 · EPS (TTM) $6.14 · Net margin 29.4% · Return on equity 14.4% · Return on assets (EBIT) 9.9% · Operating margin 29.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 86 out of 100 (medium confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 4% below its 52-week high and 105% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −52% fair-value upside, at 10%, VEEV screens cheaper than that median.
Fair Value models
Bear$210.12Fair Value $341.69Bull$444.21
Price $310.10 · Upside +10.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 9 months old). Earnings retained since then ($4.69 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Plus 30 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+16.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.9%
Start year 2021 (pandemic). Over 10 years: +22.8% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+36.8%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+22.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+22.0%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.18.1% vs 30.6%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.26% → 29%
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+16.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+11.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +14.1% a year for the price and +8.8% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Veeva maintains a solid moat through high margins and niche positioning in health information services, while limited insider and human capital signals form its main weak point.
Main risk: Customers could switch to Salesforce Life Sciences Cloud rather than adopting Veeva Vault CRM as the legacy platform relationship ends in 2030, cutting commercial subscription revenue.
Bull case: Veeva could deepen Vault platform adoption and use its agentic AI tools to increase stickiness with both large pharma and emerging biotechs, offsetting any CRM losses through broader R&D and quality revenue.
Bear case: If CRM customers migrate to Salesforce and key accounts reduce spending amid IQVIA competition, Veeva could see slower growth and margin pressure in its commercial segment while struggling to fully offset with newer areas.
Veeva is layering agentic AI features onto its Vault CRM and data tools, with clients like Roche and AstraZeneca already scaling connected engagement and compliant content workflows. The company’s regulated-industry focus gives it a durable edge in life sciences, yet general AI platforms are also entering the space. Does deeper AI integration mainly widen its moat through sticky, evidence-driven customer relationships, or does it invite new competitive pressure on core workflows?
Compare Veeva Systems Inc Class A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 119 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score73 · Top 25%
Fair Value upside+10.2% · Above median
Profitability
Return on equity (12 months)14.4% · Top 25%
Return on assets10.1% · Top 25%
Net margin (12 months)29.4% · Top 25%
Operating margin (12 months)29.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)17.6% · Above median
Valuation Multiplesvs Health Information Services median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Veeva Systems Inc Class A Fair Value". https://www.fairvalue-calculator.com/stock/VEEV
Frequently asked questions
Is Veeva Systems Inc Class A (VEEV) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of $341.69 versus a price of $310.10, about +10% upside (fairly valued).
What is the fair value of VEEV?
Our model-based fair value for Veeva Systems Inc Class A is $341.69 (as of Nov 5, 2026), built from audited fundamentals. The current price: $310.10.
What is the quality score of VEEV?
Veeva Systems Inc Class A has a Quality Score of 73/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Veeva Systems Inc Class A (VEEV)?
Our model-based price target is the fair value of $341.69 (as of Nov 5, 2026) from 24 valuation models. Cautious scenario $210.12, optimistic scenario $444.21. It is a calculation from audited fundamentals, not an analyst target.
What is the Veeva Systems Inc Class A stock forecast for 2026?
Our models put fair value at $341.69, about +10% upside versus a price of $310.10 (fairly valued). Cautious scenario $210.12, optimistic scenario $444.21. The calculation is refreshed regularly with new filings.
What is the revenue of Veeva Systems Inc Class A (VEEV)?
Veeva Systems Inc Class A reported trailing-twelve-month revenue of about $3.5B (latest available figure, as of Nov 5, 2026).
What growth is priced into Veeva Systems Inc Class A (VEEV)?
For today's price to be fair in a discounted-cash-flow model, Veeva Systems Inc Class A would have to grow free cash flow by +16.9 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +16.9 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of VEEV use?
Our models discount Veeva Systems Inc Class A at 9.1 %: a base by market capitalisation (large), damped by beta 0.93, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Veeva Systems Inc Class A that is +16.9 % per year a year over ten years, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has Veeva Systems Inc Class A (VEEV) delivered so far?
Over the past 5 years revenue at Veeva Systems Inc Class A grew +16.9 % a year. The price currently implies +16.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Veeva Systems Inc Class A (VEEV) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Veeva Systems Inc Class A (+16.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Veeva Systems Inc Class A (VEEV)?
The free-cash-flow yield on the price is 2.68 %: that much free cash flow Veeva Systems Inc Class A produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Veeva Systems Inc Class A (VEEV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Veeva Systems Inc Class A it is $341.69 per share (as of Nov 5, 2026), against a price of $310.10. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Veeva Systems Inc Class A stock overvalued or undervalued in 2026?
As of Nov 5, 2026, VEEV trades below its calculated fair value: price $310.10, fair value $341.69, a gap of about +10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VEEV?
No. The price is what the market pays today ($310.10); the fair value is what the company's own numbers justify ($341.69). For Veeva Systems Inc Class A the two are $31.59 per share apart. That gap is exactly why we show both numbers side by side.
How much is Veeva Systems Inc Class A worth?
The market values Veeva Systems Inc Class A at about $51.8B (market capitalisation, as of Nov 5, 2026). Per share that is $310.10; our models calculate a fair value of $341.69 per share.
What do the bullish and bearish scenarios say about VEEV?
Our models span a range for Veeva Systems Inc Class A: cautious scenario $210.12, base $341.69, optimistic $444.21 per share (as of Nov 5, 2026, price $310.10). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of VEEV?
Veeva Systems Inc Class A trades at a price-to-earnings ratio of 50.5 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $341.69 is built from several models across several years. Excluding one-off items of fiscal year 2026 it is 48.5 (reported for FY2026: 57.0). Median P/E at fiscal year-end, 10 fiscal years (2017 to 2026), reported earnings, FY2017, FY2018 ex one-offs: 71.1. Other multiples: PEG 1.2, P/B 7.2, P/S 15.0, EV/EBITDA 46.8.
What is the PEG ratio of VEEV?
The PEG ratio of Veeva Systems Inc Class A is 1.21 (P/E divided by earnings growth, as of Nov 5, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Veeva Systems Inc Class A (VEEV)?
Balance-sheet figures for Veeva Systems Inc Class A (as of Nov 5, 2026): return on equity 14.4%. They feed the Quality Score of 73/100, which measures business quality independently of the share price.
How far is VEEV from its 52-week high?
Veeva Systems Inc Class A trades at $310.10, about 4% below its 52-week high of $323.04 and 105% above the low of $151.43 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $341.69 is for.
Which stocks are comparable to Veeva Systems Inc Class A?
From the same area (Healthcare) we also value Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, HealthEquity, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Veeva Systems Inc Class A stock attractive at the current price?
The data as of Nov 5, 2026: price $310.10, calculated fair value $341.69 (+10%), Quality Score 73/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VEEV calculated?
We run Veeva Systems Inc Class A through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $341.69, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Veeva Systems Inc Class A currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Veeva Systems Inc Class A (VEEV)?
The closing price on Nov 5, 2026 was $310.10. Our model-based fair value is $341.69, about +10% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Veeva Systems Inc Class A right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($210.12 to $444.21) leaves room in how you read the outcome.
Where does the earnings growth of Veeva Systems Inc Class A (VEEV) come from?
Earnings per share at Veeva Systems Inc Class A grew +30.5 % a year from 2015 to 2026. Broken into its drivers: revenue per share +21.5 %, EBIT margin +1.6 %, tax rate +2.4 %, residual (interest, one-offs) +3.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Veeva Systems Inc Class A
How large is the market capitalisation of Veeva Systems Inc Class A (VEEV)?
The market capitalisation of Veeva Systems Inc Class A is $51.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Veeva Systems Inc Class A (VEEV)?
The price-to-sales ratio of Veeva Systems Inc Class A is 15.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Veeva Systems Inc Class A (VEEV)?
Earnings per share at Veeva Systems Inc Class A are $6.14 (price ÷ EPS = P/E 50.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Veeva Systems Inc Class A (VEEV)?
The net margin of Veeva Systems Inc Class A is 29.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Veeva Systems Inc Class A (VEEV)?
The return on equity (ROE) of Veeva Systems Inc Class A is 14.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Veeva Systems Inc Class A (VEEV)?
On an EBIT basis the return on assets of Veeva Systems Inc Class A is 9.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Veeva Systems Inc Class A (VEEV)?
The operating margin of Veeva Systems Inc Class A is 29.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Veeva Systems Inc Class A (VEEV)?
Revenue at Veeva Systems Inc Class A is growing +17.6% versus a year earlier (3y avg +14.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Veeva Systems Inc Class A (VEEV)?
Earnings per share at Veeva Systems Inc Class A are growing +39.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Veeva Systems Inc Class A (VEEV) hold?
Veeva Systems Inc Class A holds more cash than debt, $1.3B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Veeva Systems Inc Class A in the live analysis
One click puts Veeva Systems Inc Class A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 5, 2026